SEC Form 4 · accession 0000886163-18-000140

LIGAND PHARMACEUTICALS INC · LGND

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and COO

Period of report

Oct 1, 2018

Accepted (ET)

Oct 2, 2018 · 6:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000886163

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Oct 1, 2018	M	2,088	$9.97	A	105,388	D
Common Stock^F1	Oct 1, 2018	M	12,000	$14.47	A	117,388	D
Common Stock^F1,F2	Oct 1, 2018	S	12,000	$273.88	D	105,388	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F3	$9.97	Oct 1, 2018	M	2,088	D	—	Apr 18, 2021	Common Stock	2,088	37,894	D
Employee Stock Option (right to buy)^F1,F4	$14.47	Oct 1, 2018	M	12,000	D	—	Feb 9, 2022	Common Stock	12,000	21,675	D

F1The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 24, 2018, in accordance with Rule 10b5-1.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.12 to $276.98, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 04/18/11.
F4Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12.